ArticlePloS one2013
CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- The CD160-HVEM axis at the crossroads of tolerance and immunity: lessons from cancer for autoimmunity and transplantation.Frontiers in immunology · 2026Review
- Virus-specific Th17 Cells Are Induced by Human Cytomegalovirus after Renal Transplantation.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.Breast cancer research : BCR · 2024Article
- Comprehensively analysis of immunophenotyping signature in triple-negative breast cancer patients based on machine learning.Frontiers in pharmacology · 2023Article
- miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- Associations between CD160 polymorphisms and autoimmune thyroid disease: a case-control study.BMC endocrine disorders · 2021Article
- CD160 Stimulates CD8ImmunoHorizons · 2018Article
- HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.Frontiers in immunology · 2018Article
- Associations betweenOncotarget · 2017Article
- Pregnancy promotes tolerance to future offspring by programming selective dysfunction in long-lived maternal T cells.Journal of leukocyte biology · 2017Article
- T Cells Going Innate.Trends in immunology · 2016Review
- Increased Heterologous Protein Expression in Drosophila S2 Cells for Massive Production of Immune Ligands/Receptors and Structural Analysis of Human HVEM.Molecular biotechnology · 2015Article
- Interleukin-22 and CD160 play additive roles in the host mucosal response to Clostridium difficile infection in mice.Immunology · 2015Article
- CD160 is essential for NK-mediated IFN-γ production.The Journal of experimental medicine · 2015Article
- New insights into T-cell cosignaling in allograft rejection and survival.Current opinion in organ transplantation · 2015Review
- Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 4 countries.
Funding
Abstract
CD160 is a cell surface molecule expressed by most NK cells and approximately 50% of CD8(+) cytotoxic T lymphocytes. Engagement of CD160 by MHC class-I directly triggers a costimulatory signal to TCR-induced proliferation, cytokine production and cytotoxic effector functions. The role of CD160 in alloimmunity is unknown. Using a newly generated CD160 fusion protein (CD160Ig) we examined the role of the novel costimulatory molecule CD160 in mediating CD4(+) or CD8(+) T cell driven allograft rejection. CD160Ig inhibits alloreactive CD8(+) T cell proliferation and IFN-γ production in vitro, in particular in the absence of CD28 costimulation. Consequently CD160Ig prolongs fully mismatched cardiac allograft survival in CD4(-/-), CD28(-/-) knockout and CTLA4Ig treated WT recipients, but not in WT or CD8(-/-) knockout recipients. The prolonged cardiac allograft survival is associated with reduced alloreactive CD8(+) T cell proliferation, effector/memory responses and alloreactive IFN-γ production. Thus, CD160 signaling is particularly important in CD28-independent effector/memory CD8(+) alloreactive T cell activation in vivo and therefore may serve as a novel target for prevention of allograft rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.